Sustained control of graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe graves' orbitopathy

Thyroid

Volumn 21, Issue 9, 2011, Pages 951-956

  Laurberg, Peter ^a   Berman, Dalia C ^a   Andersen, Stig ^a   Bülow Pedersen, Inge ^a  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE; PROPYLTHIOURACIL; THIAMAZOLE; THIONAMIDE; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CUTANEOUS VASCULITIS; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOCRINE OPHTHALMOPATHY; EUTHYROIDISM; FEASIBILITY STUDY; FEMALE; GRAVES DISEASE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN ULCER; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION;

ADULT; ANTITHYROID AGENTS; BIOLOGICAL MARKERS; DENMARK; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; GRAVES DISEASE; GRAVES OPHTHALMOPATHY; HORMONE REPLACEMENT THERAPY; HOSPITALS, UNIVERSITY; HUMANS; IMMUNOGLOBULINS, THYROID-STIMULATING; MALE; METHIMAZOLE; MIDDLE AGED; PROPYLTHIOURACIL; RECURRENCE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; THYROXINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 80052476458     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2011.0039     Document Type: Article

References (34)

1. Bahn RS 2010 Mechanisms of disease. Graves' ophthalmopathy. New Engl J Med 362:726-738.
2. Wiersinga WM, Prummel MF, Terwee CB 2004 Effects of Graves' ophthalmopathy on quality of life. J Endocrinol Invest 27:259-264. (Pubitemid 38607479)
3. Alexander EK, Larsen PR 2002 High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 287:1073-1077. (Pubitemid 36121068)
4. Eckstein AK, Lax H, Lösch C, Glowacka D, Plicht M, Mann K, Esser J, Morgenthaler NG 2007 Patients with severe Graves' ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Clin Endocrinol 67:607-612. (Pubitemid 47416321)
5. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R 1990 Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Arch Intern Med 150:1098-1101. (Pubitemid 20155338)
6. Tallstedt L, Lundell G, Tørring O, Wallin G, Ljunggren JG, Blomgren H, Taube A 1992 Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N Engl J Med 326:1733-1738.
7. Tallstedt L, Lundell G, Blomgren H, Bring J 1994 Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine therapy? Eur J Endocrinol 130:494-497. (Pubitemid 24165777)
8. Acharya SH, Avenell A, Philip S, Burr J, Bevan JS, Abraham P 2008 Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review. Clin Endocrinol 69:943-950.
9. Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall- Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Currò N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marinò M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM 2008 Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Thyroid 18:333-346. (Pubitemid 351415802)
10. Bartalena L, Tanda ML 2009 Clinical practice. Graves' ophthalmopathy. N Engl J Med 360:994-1001.
11. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Tørring O 2008 TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 158:69-75. (Pubitemid 351211042)
12. Abraham P, Avenell A, Park CM, Watson WA, Bevan JS 2005A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endocrinol 153:489-498. (Pubitemid 41556274)
13. Laurberg P 2006 Remission of Graves' disease during antithyroid drug therapy. Time to reconsider the mechanism? Eur J Endocrinol 155:783-786. (Pubitemid 46040614)
14. Shizume K 1978 Long term antithyroid drug therapy for intractable cases of Graves' disease. Endocrinol Jpn 25: 377-379. (Pubitemid 9006900)
15. Slingerland DW, Burrows BA 1979 Long-term antithyroid treatment in hyperthyroidism. JAMA 242:2408-2410. (Pubitemid 10160538)
16. Lippe BM, Landaw EM, Kaplan SA 1987 Hyperthyroidism in children treated with long term medical therapy: twentyfive percent remission every two years. J Clin Endocrinol Metab 64:1241-1245. (Pubitemid 17074785)
17. Azizi F, Ataie L, Hedayati M, Mehrabi Y, Sheikholeslami F 2005 Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. Eur J Endocrinol 152:695-701. (Pubitemid 40744537)
18. Mazza E, Carlini M, Flecchia D, Blatto A, Zuccarini O, Gamba S, Beninati S, Messina M J 2008 Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study. J Endocrinol Invest 31:866-872.
19. Laurberg P, Andersen S, Karmisholt J 2006 Anti-thyroid drug therapy of Graves' hyperthyroidism: realistic goals and focus on evidence. Exp Rev Endocrinol Metab 1:91-102.
20. Pedersen IB, Knudsen N, Perrild H, Ovesen L, Laurberg P 2001 TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves' disease and multinodular toxic goitre: a comparison of two competitive binding assays. Clin Endocrinol 55:381-390. (Pubitemid 32823048)
21. Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P, Léger J 2008 French Childhood Graves' Disease Study Group. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab 93:3817-3826.
22. Laurberg P, Buchholtz Hansen PE, Iversen E, Eskjaer Jensen S, Weeke J 1986 Goitre size and outcome of medical treatment of Graves' disease. Acta Endocrinol 111:39-43. (Pubitemid 16187044)
23. Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A 1997 Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 7:369-375. (Pubitemid 27295133)
24. Glinoer D, de Nayer P, Bex M 2001 Effects of L-thyroxine administration, TSH-receptor antibodies and smoking o n therisk of recurrence of Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol 144:475-483. (Pubitemid 32487523)
25. Nedrebo BG, Holm PI, Uhlving S, Sorheim JI, Skeie S, Eide GE, Husebye ES, Lien EA, Aanderud S 2002 Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease. Eur J Endocrinol 147:583-589. (Pubitemid 35414555)
26. Roti E, Gardini E, Minelli R, Bianconi L, Salvi M, Gavaruzzi G, Braverman LE 1993 Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism. J Clin Endocrinol Metab 76:928-932. (Pubitemid 23110840)
27. Elbers L, Mourits M, Wiersinga W 2011 Outcome of very long-term treatment with antithyroid drugs in graves' hyperthyroidism associated with Graves' orbitopathy. Thyroid 21:279-283.
28. Cooper DS 2005 Antithyroid drugs. N Engl J Med 352: 905-917. (Pubitemid 40300299)
29. Cooper DS, Goldminz D, Levin AA, Ladenson PW, Daniels GH, Molitch ME, Ridgway EC 1983 Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med 98:26-29. (Pubitemid 13217959)
30. Takata K, Kubota S, Fukata S, Kudo T, Nishihara E, Ito M, Amino N, Miyauchi A 2009 Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30mg daily than with 15mg daily. Thyroid 19:559-563.
31. Noh JY, Yasuda S, Sato S, Matsumoto M, Kunii Y, Noguchi Y, Mukasa K, Ito K, Ito K, Sugiyama O, Kobayashi H, Nihojima S, Okazaki M, Yokoyama S 2009 Clinical characteristics of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis caused by antithyroid drugs. J Clin Endocrinol Metab 94:2806-2811.
32. Gunton JE, Stiel J, Clifton-Bligh P, Wilmshurst E, McElduff A 2000 Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving anti-thyroid medication. Eur J Endocrinol 142:587-590. (Pubitemid 30399488)
33. Cooper DS, Rivkees SA 2009 Putting propylthiouracil in perspective. J Clin Endocrinol Metab 94:1881-1882.
34. Bahn RS, Burch HS Cooper DS, Garber JR, Greenlee CM, Klein IL, Laurberg P, McDougall IR, Rivkees SA, Ross D, Sosa JA, Stan MN 2009 The role of Propylthiouracil in the management of Graves' disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 19:673-674.